GeneDx Holdings Corp. Class A Common Stock (WGS) Stock Price
WGSStock
$63.61−46.28%52W
Market Cap$1.90B
P/E—
PEG Ratio—
Div yield—
Beta2.03
WGS Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-14.77%
Price vs S&P 500 (4W)-33.65%
VGM Score39.40
WGS Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.19 | $0.01 | +105.33%(+$0.20) | |
| Q1 2026 | -$0.02 | -$0.28 | -1407.81%(-$0.26) | |
| Q4 2025 | $0.12 | $0.14 | +16.67%(+$0.02) | |
| Q3 2025 | $0.42 | $0.49 | +15.88%(+$0.07) | |
| Q2 2025 | $0.11 | $0.50 | +371.70%(+$0.39) |
WGS Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.23
4.23
4.23
4.23
Industry Peers — Health Services(21)
| Symbol | Value Score | Growth Score | Momentum Score | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
WGSGeneDx Holdings Corp. Class A Common Stock | F | B | D | — | 25.4% | -21.8% | -38.7% | $63.61 |
| LFSTLifeStance Health Group, Inc. Common Stock | D | A | B | 464.3x | 61.1% | 4.9% | 3.4% | $11.74 |
| PRVAPrivia Health Group, Inc. Common Stock | C | B | C | 125.5x | 24.1% | 1.9% | 3.8% | $22.52 |
| PNTGThe Pennant Group, Inc. Common Stock | D | B | B | 49.4x | 37.9% | 5.7% | 9.5% | $41.87 |
| USPHUS Physical Therapy Inc | C | D | C | 32.3x | 11.3% | 9.4% | 6.8% | $85.71 |
| INNVInnovAge Holding Corp. Common Stock | D | C | C | — | 15.9% | 0.3% | -1.1% | $8.85 |
| OMDAOmada Health, Inc. Common Stock | D | B | D | — | 8.3% | -0.8% | 1.8% | $17.63 |
| PIIIP3 Health Partners Inc. Common Stock | A | C | D | — | 2.8% | -9.9% | 10.3% | $4.14 |
| SRTAStrata Critical Medical, Inc. Class A Common Stock | B | B | C | 9.7x | 18.8% | -8.0% | 14.3% | $4.54 |
| ALPSALPS Group Inc Ordinary Share | — | — | D | — | — | — | — | $0.34 |
| EUDAEUDA Health Holdings Limited Ordinary Shares | C | B | C | — | 66.9% | -36.5% | -1.8% | $15.40 |
About GeneDx Holdings Corp. Class A Common Stock
GeneDx Holdings develops exome and genome sequencing technologies for diagnosing rare and ultra-rare pediatric genetic disorders. The company addresses a growing market opportunity as genetic testing becomes the standard diagnostic approach, enabling earlier diagnoses and improved patient outcomes. With a core business in pediatric and rare disease diagnostics, GeneDx is expanding into data and information services as precision medicine adoption accelerates.